SciELO - Scientific Electronic Library Online

vol.50 issue2Secondary metabolites of species of the Myristicaceae family that produce enzymatic inhibitionEvaluation of the mineral-medicinal water of Presidencia Roque Sáenz Peña, Chaco province, Argentina author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista Colombiana de Ciencias Químico - Farmacéuticas

Print version ISSN 0034-7418On-line version ISSN 1909-6356


QUIROGA ROBAYO, Lizeth Daniela; MONTANO AVILA, Mónica Patricia  and  LOPEZ GUTIERREZ, José Julián. Study of the use of IVIG Normal Human Immunoglobulin in the La Samaritana University Hospital during the period of 2017-2019. Rev. colomb. cienc. quim. farm. [online]. 2021, vol.50, n.2, pp.386-405.  Epub Oct 29, 2021. ISSN 0034-7418.


Non-specific intravenous human immunoglobulin (IVIG) is a valuable therapeutic resource in specific pathologies, however, there are pathological conditions for which there is not yet a defined therapeutic strategy and due to similarity or biological plausibility, some prescribers end up using it.


To identify the indications for which IVIG has been prescribed in the HUS.


A descriptive observational cross-sectional study was performed with retrospective collection of information between January 1, 2017, and December 31, 2019.

Materials and methods:

180 medical records were reviewed, demographic characterization of the study, clinical and pharmacological population of patients who have been prescribed at least one dose of immunoglobulin. In addition, the indications proposed in the clinical history were compared with the indications approved by regulatory authority (Invima).


It was determined that the population with the highest predominance to which IVIG was prescribed in the HUS, were women in young adulthood. Likewise, the use of IVIG presented a higher frequency in patients with idiopathic purple thrombocytopenia (ITP), Guillain-Barré Syndrome (GBS), Systemic Lupus Erythematosus (SLE) and neonatal jaundice due to other existing hemolysis specified as main diagnoses. The indications for which there is an Invima approval are nonspecific, which means that there is no defined therapeutic strategy with IVIG and therefore that prescribers for similarity or biological plausibility turn out to be using it, for uses not indicated in the sanitary registry (UNIRS), which represented 71 % of indications for which IVIG was prescribed in HUS.


The indications for the most prescription with IVIG were idiopathic purple thrombocytopenia (ITP) and Guillain-Barré syndrome (GBS). The non-prescribed use of IVIG in this study reached a figure of 71%.

Keywords : Non-specific intravenous human immunoglobulin (IVIG); drug utilization; off-label use.

        · abstract in Spanish | Portuguese     · text in English     · English ( pdf )